Genomenon Inc.

Genomenon Inc.

Private
Ann Arbor, MichiganHealthcare & Life Scienceshttps://www.genomenon.com/

Last Round

Series B

Mar 10, 2022

Total Funding Raised

$33.1M

Momentum Score

25 /100

Company Overview

Genomenon Inc. is an AI-driven genomics company that provides software, data, and services for genomic information analysis to support clinical and pharmaceutical organizations.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Medical AI, Drug Discovery, Healthcare Analytics

Business Model

B2B

Customer Profile

Subscription SaaS, Data as a Service, Services & Consulting, Freemium, Government Contracts

AI Layer

Application

Keywords

variant interpretationgenomic search engineAI genomicsevidence curationgene variant databasecancer genomicsrare disease diagnosisvariant classificationprecision medicinevariant curation servicesdrug discoverygenomic intelligence platformgenomic data APIgenomic literature mininggenomic language processing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genomenon Inc. Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Genomenon Inc. Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMar 10, 2022
GrantFeb 15, 2022
Series AMar 16, 2021
SeedJan 8, 2019
GrantApr 25, 2017
Seed
Nov 10, 2016

Key People

Founding team and executive leadership

Mark J. Kiel

Chief Science Officer Founder

Founding Team

Mike Klein

Chief Executive Officer

Executive Team

Brian Groark

Chief Financial Officer

Executive Team

Samuel Globus

Chief Operating Officer

Executive Team

Genomenon Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 22, 2026

    Monthly visitors increased 45% MoM, reaching 32.8K.

  • Aug 21, 2025

    Monthly visitors grew 49% MoM, reaching 26.4K.

Genomenon Inc. Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genomenon Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Genomenon Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersAnn Arbor, Michigan
Employee Range140
Year Founded2014
Last FundingMar 10, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.